Cardiol Therapeutics Inc Quick Ratio (CRDL) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cardiol Therapeutics inc   (NASDAQ: CRDL)

Cardiol Therapeutics Inc 's Quick Ratio

CRDL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 3.79 a new company low.

Within Biotechnology & Pharmaceuticals industry 69 other companies have achieved higher Quick Ratio than Cardiol Therapeutics Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 677 to 785.

Explain Quick Ratio?
How much Cash & cash equivalents CRDL´s has?
What are CRDL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRDL Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -19.33 % -19.33 % -19.33 % -19.33 % -15.5 %
Y / Y Cash & cash equivalent Change -29.97 % -29.97 % -29.97 % -29.97 % -12.46 %
Quick Ratio MRQ 3.79 3.79 3.79 3.79 4.36
CRDL's Total Ranking # 785 # 677 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -19.33 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -29.97 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 70
Healthcare Sector # 341
Overall Market # 785


Quick Ratio Statistics
High Average Low
6.07 4.61 3.79
(Dec 31 2022)   (Dec 31 2025)




Financial Statements
Cardiol Therapeutics Inc 's Current Liabilities $ 4 Millions Visit CRDL's Balance sheet
Cardiol Therapeutics Inc 's Cash & cash equivalent $ 16 Millions Visit CRDL's Balance sheet
Source of CRDL's Sales Visit CRDL's Sales by Geography


Cumulative Cardiol Therapeutics Inc 's Quick Ratio

CRDL's Quick Ratio for the trailling 12 Months

CRDL Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -19.33 % -18.24 % -17.25 % -16.34 % -15.5 %
Y / Y Cash & cash equivalent TTM Growth -29.97 % -25.14 % -20.63 % -16.41 % -12.46 %
Quick Ratio TTM 3.79 3.96 4.11 4.24 4.36
Total Ranking TTM # 4261 # 3461 # # #
Seq. Current Liabilities TTM Growth -5.65 % -5.35 % -5.08 % -4.83 % -4.38 %
Seq. Cash & cash equivalent TTM Growth -9.66 % -8.81 % -8.1 % -7.49 % -3.44 %

Quick ratio ranking by company, industry and sector >> Back to CRDL Financial Strength Comparisons >> Go to Compare CRDL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CRDL's Current Liabilities to $4.33 millions, cumulative Quick Ratio to 3.79 below the CRDL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Quick Ratio than Cardiol Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3461 to 4261.

Explain Quick Ratio?
How much Cash & cash equivalents CRDL´s has?
What are CRDL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 155
Healthcare Sector # 965
Within the Market # 4261


trailing twelve months Quick Ratio Statistics
High Average Low
6.07 4.61 3.79
(Dec 31 2022)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Immunovant Inc   10.40 $ 713.971  Millions$ 68.677  Millions
Cullinan Therapeutics Inc   10.22 $ 377.896  Millions$ 36.961  Millions
X4 Pharmaceuticals Inc  9.82 $ 252.998  Millions$ 25.757  Millions
Molecular Partners Ag  9.44 $ 104.149  Millions$ 11.027  Millions
4d Molecular Therapeutics Inc   9.15 $ 402.655  Millions$ 43.985  Millions
Prokidney Corp   9.10 $ 270.017  Millions$ 29.671  Millions
Sab Biotherapeutics Inc   9.04 $ 96.592  Millions$ 10.681  Millions
Denali Therapeutics Inc   8.82 $ 867.879  Millions$ 98.351  Millions
Artiva Biotherapeutics Inc   8.25 $ 108.008  Millions$ 13.087  Millions
Black Diamond Therapeutics Inc   8.18 $ 128.652  Millions$ 15.731  Millions
Zura Bio Limited  8.02 $ 109.407  Millions$ 13.647  Millions
Aura Biosciences Inc   7.85 $ 144.241  Millions$ 18.383  Millions
Replimune Group Inc   7.76 $ 483.804  Millions$ 62.362  Millions
Allogene Therapeutics Inc   7.70 $ 250.210  Millions$ 32.514  Millions
Compugen Ltd  7.67 $ 145.640  Millions$ 18.999  Millions
Voyager Therapeutics Inc   7.40 $ 196.447  Millions$ 26.541  Millions
Scholar Rock Holding Corp  7.37 $ 367.563  Millions$ 49.869  Millions
Krystal Biotech Inc   7.27 $ 827.791  Millions$ 113.861  Millions
Metagenomi Therapeutics Inc   7.01 $ 160.799  Millions$ 22.933  Millions
Fennec Pharmaceuticals Inc   7.00 $ 73.576  Millions$ 10.518  Millions
Odyssey Therapeutics, Inc.  6.85 $ 181.358  Millions$ 26.475  Millions
Invivyd Inc   6.64 $ 226.689  Millions$ 34.163  Millions
Entera Bio Ltd   6.59 $ 7.108  Millions$ 1.079  Millions
Tenaya Therapeutics Inc   6.51 $ 100.547  Millions$ 15.436  Millions
Repligen Corp  6.51 $ 767.628  Millions$ 117.859  Millions
Engene Therapeutics Inc   6.47 $ 193.736  Millions$ 29.965  Millions
Acumen Pharmaceuticals Inc   6.03 $ 116.865  Millions$ 19.391  Millions
Solid Biosciences Inc   5.99 $ 187.850  Millions$ 31.369  Millions
Century Therapeutics inc   5.79 $ 117.114  Millions$ 20.226  Millions
Neumora Therapeutics Inc   5.67 $ 182.530  Millions$ 32.167  Millions

Date modified: 2026-07-07T10:06:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.